Vedolizumab: A review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease

BioDrugs

Volumn 29, Issue 1, 2015, Pages 57-67

  Garnock Jones, K P ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VEDOLIZUMAB; MONOCLONAL ANTIBODY;

ADULT; CROHN DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; MAINTENANCE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; ULCERATIVE COLITIS; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925485488     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-014-0113-2     Document Type: Review

References (28)

1. Mosli M, Rivera-Nieves J, Feagan B. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drugs. 2014;74(3):297-311.
2. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29(4):397-404.
3. Cheng FK, McLean LP, Cross RK. What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med. 2014. doi: 10.3978/j:issn.2305-5839.2013.10.01.
4. European Medicines Agency. Entyvio® (vedolizumab for intravenous infusion): EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002782/WC500168528.pdf. Accessed 28 Oct 2014.
5. Takeda Pharmaceuticals America Inc. Entyvio® (vedolizumab for intravenous infusion): US prescribing information. 2014. http://general.takedapharm.com/content/file.aspx?filetypecode=ENTYVIOPI&CountryCode=US&LanguageCode=EN. Accessed 28 Oct 2014.
6. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864-75.
7. Haanstra KG, Hofman SO, Lopes Estevao DM et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190(5):1961-73.
8. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264(1-2):123-6.
9. Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18(11):2107-19.
10. Rosario M, Fox I, Milch C, et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 [abstract no. P-140]. Inflamm Bowel Dis. 2013;19(Suppl. 1):S80.
11. Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. Abs. 2013;5(6):842-50.
12. Parikh A, Wyant T, Clifford DB, et al. No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic progenitor cells after treatment with vedolizumab, a humanized monoclonal antibody to alpha4beta7 integrin [abstract no. 1008]. Gastroenterology. 2010;1:S145-6.
13. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2014. doi: 10.1136/gutjnl-2014-307127.
14. Dirks NL, Rosario M, Gastonguay MR et al. Population pharmacokinetic modeling of vedolizumab in patients with ulcerative colitis or Crohn's disease [abstract no. Mo1225]. Gastroenterology. 2014;146(5 Suppl. 1):S591.
15. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
16. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21.
17. French J, Rosario M, Dirks NL et al. Exposure-response relationship of vedolizumab treatment in adults with ulcerative colitis [abstract no. Mo1229]. Gastroenterology. 2014;146(5 Suppl. 1):S592.
18. French J, Rosario M, Dirks NL et al. Vedolizumab exposure-response relationship during induction therapy in adults with Crohn's disease [abstract no. Mo1231]. Gastroenterology. 2014;146(5 Suppl. 1):S592-S3.
19. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470-9.
20. Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691-9.
21. Feagan BG, McDonald J, Greenberg G et al. An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis (UC) [abstract no. 4851]. Gastroenterology. 2000;118(4 Suppl. 2):A874.
22. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med. 2005;352(24):2499-507.
23. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370-7.
24. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618-27 e3.
25. Feagan B, Colombel JF, Rubin D, et al. Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab [abstract no. DOP076]. J Crohns Colitis. 2014;8:S51-2.
26. Feagan B, Sandborn WJ, Smyth M, et al. Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders [abstract no. P501]. J Crohns Colitis. 2014;8:S276-7.
27. Sandborn WJ, Feagan B, Reinisch W et al. Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6 [abstract no. P497]. J Crohns Colitis. 2014;8(Suppl. 1):S274-S5.
28. Colombel JF, Sands B, Hanauer S, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or crohn's disease [abstract no. 1674]. Am J Gastroenterol. 2013;108:S502-3.